SURMOUNT-4: Tirzepatide Withdrawal Linked to 20 Percentage-P

Phase 3 data show patients with obesity who maintained tirzepatide from weeks 36 to 88 continued significant weight loss versus patients switched to placebo.

Related Keywords

Jeff Emmick , Louisj Aronne , Division Of Endocrinology , Weight Control Center , Comprehensive Weight Control Center , Weill Cornell Medicine , Surmount 4 , Tirzepatide , Weight Loss , Weight Gain , Placebo , Withdrawal , Maintain , Long Term , Lilly ,